A Post-Market Assessment of the Safety and Performance of the TriClip™ System
At a glance
Conditions
NCT07586995
Where you'd take part
This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Ascension Texas Cardiovascular Research
Austin, Texasstudy coordinator listed
Recruiting
Hospital Clínic de Barcelona
Barcelona, Spainstudy coordinator listed
Recruiting
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spainstudy coordinator listed
Recruiting
Northwestern Memorial Hospital
Chicago, Illinoisstudy coordinator listed
Recruiting
Ospedale San Raffaele - Cardiac
Milan, Lombard, Italystudy coordinator listed
Not yet recruiting
Scripps Health
La Jolla, Californiastudy coordinator listed
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Meghan Griffin · STUDY_DIRECTOR · Abbott
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Rate of Peri-Procedural Adverse EventsThrough 30 days post-procedure
Defined as all-cause mortality, device embolization, device thrombosis, non-elective surgery or transcatheter intervention for device- or procedure-related adverse event (AE) new pacemaker implantation and device- or procedure related major bleeding
- Tricuspid Regurgitation (TR) grade less than or equal to moderateAt 30-day follow-up
- Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score improvement of at least 10 pointsAt 30-day follow-up
All KCCQ scores are scaled from 0 (worst) to 100 (best possible status), where the higher score reflects a better health status.